EUVIMEDEUVIMED entdecken
Crossref

Deciphering the molecular mechanism of sesamol in inflammatory bowel disease through an integrative computational and biological evaluation of the JAK1 signalling pathway

Krishnendu Prayaga Rajappan, Sonu Benny, Vishnu Vasanthi Radhakrishnan, Aneesh Thankappan Presanna, Leena K Pappachen, Marcus Tullius Scotti, Krishnadas Madhu, Bijo Mathew, Subin Mary Zachariah

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-026-05059-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Krishnendu Prayaga Rajappan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, Kerala, 682041, In…. Hauptthemen laut MEDLINE: Benzodioxoles, Phenols, Janus Kinase 1, Anti-Inflammatory Agents. Die Arbeit nennt 90 Literaturangaben. Gefördert von: Amrita Vishwa Vidyapeetham.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD) is a major chronic inflammatory disorder whose pathogenesis involves impaired mucosal barrier function, dysbiosis, immune dysregulation, and oxidative stress. The JAK-STAT signalling axis plays a pivotal role in driving inflammatory cytokine response in IBD. Consequently, natural antioxidant and anti-inflammatory compounds have emerged as promising therapeutic candidates. This study aimed to elucidate the molecular mechanisms underlying the anti-IBD potential of sesamol through an integrative computational and experimental approach. Potential sesamol-associated targets were identified using network pharmacology and protein-protein interaction analyses. Gene Ontology and KEGG pathway enrichment were conducted to identify key biological processes and signalling pathways. Molecular docking, molecular dynamics simulations, and MM-GBSA binding free energy calculations were performed by Schrödinger V14.1.38 to evaluate interactions with Janus kinases. Therapeutic relevance was validated using dextran sulphate sodium (DSS)-induced murine colitis model. Sixty-three overlapping therapeutic targets were identified, with JAK1 and JAK2 emerging as central signalling nodes. Sesamol exhibited strong binding affinity toward both kinases, forming a more stable and sustained complex with JAK1, as evidenced by lower RMSD and RMSF values and favourable MM-GBSA energies compared with JAK2. In vivo, JAK1 expression was significantly elevated in inflamed colonic tissue and was markedly normalised following sesamol treatment, corroborating computational predictions. Sesamol exerts protective effects in IBD by modulating the JAK-STAT signalling pathway, reducing intestinal inflammation, and promoting mucosal restoration. These findings highlight sesamol as a promising multi-target natural candidate for restoring immune homeostasis and intestinal barrier integrity in IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzodioxolesPhenolsJanus Kinase 1Anti-Inflammatory AgentsInflammatory Bowel DiseasesColitisAnimalsSignal TransductionMolecular Docking SimulationJanus Kinase 2Molecular Dynamics SimulationMiceDextran SulfateHumansNetwork PharmacologyMice, Inbred C57BLMale

Stichwörter der Autor:innen

Dextran sulphate sodiumInflammatory bowel diseaseJanus kinase 1Janus kinase 2Molecular dockingMolecular dynamicsNetwork pharmacologySesamol

Substanzen

sesamolBenzodioxolesPhenolsJanus Kinase 1Janus Kinase 2Anti-Inflammatory AgentsJak1 protein, mouseDextran SulfateJak2 protein, mouse

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, Kerala, 682041, India.
  • Departamento de Química, Centro de Ciências Exatas E da Natureza, Universidade Federal da Paraíba - Campus I, Cidade Universitária, João Pessoa, PB, CEP 58051-90, Brazil.
  • Department of Pharmacology, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, Kerala, 682041, India.
  • Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, Kerala, 682041, India. bijomathew@aims.amrita.edu.
  • Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, Kerala, 682041, India. subinmaryzachariah@aims.amrita.edu.

Förderung

  • Amrita Vishwa Vidyapeetham

Zitieren

APA

Rajappan, K. P., Benny, S., Radhakrishnan, V. V., Presanna, A. T., Pappachen, L. K., Scotti, M. T., Madhu, K., Mathew, B., & Zachariah, S. M. (2026). Deciphering the molecular mechanism of sesamol in inflammatory bowel disease through an integrative computational and biological evaluation of the JAK1 signalling pathway. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05059-5

Vancouver

Rajappan KP, Benny S, Radhakrishnan VV, Presanna AT, Pappachen LK, Scotti MT, et al. Deciphering the molecular mechanism of sesamol in inflammatory bowel disease through an integrative computational and biological evaluation of the JAK1 signalling pathway. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05059-5

BibTeX
@article{Rajappan2026,
  author = {Rajappan, Krishnendu Prayaga and Benny, Sonu and Radhakrishnan, Vishnu Vasanthi and Presanna, Aneesh Thankappan and Pappachen, Leena K and Scotti, Marcus Tullius and Madhu, Krishnadas and Mathew, Bijo and Zachariah, Subin Mary},
  title = {Deciphering the molecular mechanism of sesamol in inflammatory bowel disease through an integrative computational and biological evaluation of the JAK1 signalling pathway},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-05059-5}
}
Kostenlos starten →